1. Poiesz BJ, Ruscette FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured cells of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415-9.
  2. Gallo RC, Willems L, Tagaya Y. Time to Go Back to the Original Name. Front Microbiol. 2017;8:1800.
  3. Kazanji M, Mouinga-Ondeme A, Lekana-Douki-Etenna S, Caron M, Makuwa M, Mahieux R, et al. Origin of HTLV-1 in hunters of nonhuman primates in Central Africa. J Infect Dis. 2015;211(3):361-5.
  4. Wolfe ND, Heneine W, Carr JK, Garcia AD, Shanmugam V, Tamoufe U, et al. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proceedings of the National Academy of Sciences. 2005;102(22):7994-9.
  5. Cassar O, Einsiedel L, Afonso PV, Gessain A. Human T-cell lymphotropic virus type 1 subtype C molecular variants among indigenous australians: new insights into the molecular epidemiology of HTLV-1 in Australo-Melanesia. PLoS neglected tropical diseases. 2013;7(9):e2418.
  6. Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388.
  7. European Centre for Disease Prevention and Control. Geographical distribution of areas with a high prevalence of HTLV-1 infection. Stockholm; 2015 2015.
  8. May JT, Stent G, Schnagl RD. Antibody to human T-cell lymphotropic virus type I in Australian aborigines. The Medical journal of Australia. 1988;149(2):104.
  9. Einsiedel L, Woodman RJ, Flynn M, Wilson K, Cassar O, Gessain A. Human T-Lymphotropic Virus type 1 infection in an Indigenous Australian population: epidemiological insights from a hospital-based cohort study. BMC public health. 2016;16:787.
  10. Murphy EL, Figueroa JP, Gibbs WN, Brathwaite A, Holding-Cobham M, Waters D, et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med. 1989;111(7):555-60.
  11. Roucoux D, Wang B, Smith D. A prospective study of sexual transmission of human T lymphotropic virus (HTLV)-I and HTLV-II. Journal Infectious Diseases. 2005;191(9):1490-7.
  12. Stuver SO, Tachibana N, Okayama A, Shioiri S, Tsunetoshi Y, Tsuda K, et al. Heterosexual transmission of human T cell leukemia/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study. J Infect Dis. 1993;167(1):57-65.
  13. Nunes D, Boa-Sorte N, Grassi MF, Taylor GP, Teixeira MG, Barreto ML, et al. HTLV-1 is predominantly sexually transmitted in Salvador, the city with the highest HTLV-1 prevalence in Brazil. PLoS One. 2017;12(2):e0171303.
  14. Kinoshita K, Hino S, Amagaski T, Ikeda S, Yamada Y, Suzuyama J, et al. Demonstration of adult T-cell leukemia virus antigen in milk from three sero-positive mothers. Gan. 1984;75(2):103-5.
  15. Hino S, Sugiyama H, Doi H, Ishimaru T, Yamabe T, Tsuji Y, et al. Breaking the cycle of HTLV-I transmission via carrier mothers' milk. Lancet. 1987:158-9.
  16. Percher F, Jeannin P, Martin-Latil S, Gessain A, Afonso PV, Vidy-Roche A, et al. Mother-to-Child Transmission of HTLV-1 Epidemiological Aspects, Mechanisms and Determinants of Mother-to-Child Transmission. Viruses. 2016;8(2).
  17. Paiva AM, Assone T, Haziot MEJ, Smid J, Fonseca LAM, Luiz ODC, et al. Risk factors associated with HTLV-1 vertical transmission in Brazil: longer breastfeeding, higher maternal proviral load and previous HTLV-1-infected offspring. Sci Rep. 2018;8(1):7742.
  18. Dourado I, Andrade T, Galvao-Castro B. HTLV-I in Northeast Brazil: differences for male and female injecting drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19(4):426-9.
  19. Andersson S, Ahmed R, Bredberg-Raden, Albert J, Krook A, Kall K, et al. HTLV-II infected Swedish intravenous drug users carry subtype A. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;10:280.
  20. Andrade TM, Dourado I, Galvao-Castro B. Associations among HTLV-I, HTLV-II, and HIV in injecting drug users in Salvador, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(2):186-7.
  21. Caterino-de-Araujo A, Sacchi CT, Goncalves MG, Campos KR, Magri MC, Alencar WK, et al. Short Communication: Current Prevalence and Risk Factors Associated with Human T Lymphotropic Virus Type 1 and Human T Lymphotropic Virus Type 2 Infections Among HIV/AIDS Patients in Sao Paulo, Brazil. AIDS Res Hum Retroviruses. 2015;31(5):543-9.
  22. Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T-cell leukaemia virus by blood transfusion: seroconversion in recipients. Vox Sang. 1984;46(5):245-53.
  23. Okochi K, Sato H. Transmission of Adult T-Cell Leukemia-Virus (Htlv-I) Through Blood-Transfusion and Its Prevention. Aids Research. 1986;2:S157-S61.
  24. Cook LB, Melamed A, Demontis MA, Laydon DJ, Fox JM, Tosswill JH, et al. Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients. Retrovirology. 2016;13(1):3.
  25. Montesdeoca Andrade MJ, Correa Diaz EP, Buestan ME. HTLV-1-associated myelopathy in a solid organ transplant recipient. BMJ Case Rep. 2016;2016.
  26. Ramanan P, Deziel PJ, Norby SM, Yao JD, Garza I, Razonable RR. Donor-transmitted HTLV-1-associated myelopathy in a kidney transplant recipient--case report and literature review. Am J Transplant. 2014;14(10):2417-21.
  27. Tajima Y, Matsumura M, Yaguchi H, Mito Y. Two Cases of Human T-Lymphotropic Virus Type I-Associated Myelopathy/Tropical Spastic Paraparesis Caused by Living-Donor Renal Transplantation. Case Rep Neurol Med. 2016;2016:4203079.
  28. Yamauchi J, Yamano Y, Yuzawa K. Risk of Human T-Cell Leukemia Virus Type 1 Infection in Kidney Transplantation. N Engl J Med. 2019;380(3):296-8.
  29. Satake M, Iwanaga M, Sagara Y, Watanabe T, Okuma K, Hamaguchi I. Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide retrospective cohort analysis. Lancet Infect Dis. 2016;16(11):1246-54.
  30. Paiva A, Smid J, Haziot MEJ, Assone T, Pinheiro S, Fonseca LAM, et al. High risk of heterosexual transmission of human T-cell lymphotropic virus type 1 infection in Brazil. J Med Virol. 2017;89(7):1287-94.
  31. Einsiedel L, Purcell D, Schinke S, Haynes K, Taylor GP, Martin F. Highlights from the HTLV-1 symposium at the 2017 Australasian HIV and AIDS Conference held jointly with the 2017 Australasian Sexual Health Conference, November 2017, Canberra, Australia. J Virus Erad. 2018;4(1):48-50.
  32. Alvarez C, Gotuzzo E, Vandamme AM, Verdonck K. Family Aggregation of Human T-Lymphotropic Virus 1-Associated Diseases: A Systematic Review. Front Microbiol. 2016;7:1674.
  33. Bandeira LM, Uehara SNO, Puga MAM, Rezende GR, Vicente ACP, Domingos JA, et al. HTLV-1 intrafamilial transmission among Japanese immigrants in Brazil. J Med Virol. 2017.
  34. Yao K, Hisada M, Maloney E, Yamano Y, Hanchard B, Wilks R, et al. Human T lymphotropic virus types I and II western blot seroindeterminate status and its association with exposure to prototype HTLV-I. J Infect Dis. 2006;193(3):427-37.
  35. Kuramitsu M, Sekizuka T, Yamochi T, Firouzi S, Sato T, Umeki K, et al. Proviral Features of Human T Cell Leukemia Virus Type 1 in Carriers with Indeterminate Western Blot Analysis Results. Journal of clinical microbiology. 2017;55(9):2838-49.
  36. Grassi MFR, Olavarria VN, Kruschewsky RdA, Yamano Y, Jacobson S, Taylor GP, et al. Utility of HTLV proviral load quantification in diagnosis of HTLV-1-associated myelopathy requires international standardization. Journal of Clinical Virology. 2013.
  37. Nakada K, Kohakura M, Komoda H, Hinuma Y. High incidence of HTLV antibody in carriers of Strongyloides stercoralis. Lancet. 1984;1(8377):633.
  38. Gotuzzo E, Terashima A, Alvarez H, Tello R, Infante R, Watts DM, et al. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Am J Trop Med Hyg. 1999;60(1):146-9.
  39. Gillet NA, Cook L, Laydon DJ, Hlela C, Verdonck K, Alvarez C, et al. Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo. PLoS pathogens. 2013;9(4):e1003263.
  40. Einsiedel LJ, Pham H, Woodman RJ, Pepperill C, Taylor KA. The prevalence and clinical associations of HTLV-1 infection in a remote Indigenous community. The Medical journal of Australia. 2016;205(7):305-9.
  41. Murphy E, Hanchard B, Figueroa JP, Gibbs WN, Lofters WS, Campbell M, et al. Modelling the risk of adult T-cell leukaemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer. 1989;43:250-3.
  42. Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer. 1990;45(2):237-43.
  43. Malik B, Taylor GP. Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom. Br J Haematol. 2018.
  44. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79(3):428-37.
  45. Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570-7.
  46. De Castro-Costa CM, Araujo AQ, Barreto MM, Takayanagui OM, Sohler MP, da Silva EL, et al. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses. 2006;22(10):931-5.
  47. Smadja D, Bellance R, Cabre P, Arfi S, Vernant JC. Clinical characteristics of HTLV-1 associated dermato-polymyositis. Seven cases from Martinique. Acta Neurol Scand. 1995;92(3):206-12.
  48. Martin F, Taylor GP, Jacobson S. Inflammatory manifestations of HTLV-1 and their therapeutic options. Expert Rev Clin Immunol. 2014;10(11):1531-46.
  49. Einsiedel L, Fernandes L, Spelman T, Steinfort D, Gotuzzo E. Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population. Clin Infect Dis. 2012;54(1):43-50.
  50. Einsiedel L, Cassar O, Goeman E, Spelman T, Au V, Hatami S, et al. Higher human T-lymphotropic virus type 1 subtype C proviral loads are associated with bronchiectasis in indigenous australians: results of a case-control study. Open forum infectious diseases. 2014;1(1):ofu023.
  51. Merle H, Cabre P, Olindo S, Merle S, Smadja D. Ocular lesions in 200 patients infected by the human T-cell lymphotropic virus type 1 in martinique (French West Indies). Am J Ophthalmol. 2002;134(2):190-5.
  52. K K, M T, OA, E I, N H,  MN, et al. Human T-lymphotropic virus type 1 uveitis in children. Nippon Ganka Gakkai Zasshi. 1997;101(5):538-43.
  53. Mochizuki M, Yamaguchi K, Takatsuki K, Watanabe T, Mori S, Tajima K. HTLV-I and uveitis. Lancet. 1992;339(8801):1110.
  54. La Grenade L. HTLV-I, infective dermatitis, and tropical spastic paraparesis. Molecular Neurobiology. 1994;8:147-53.
  55. LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet. 1990;336(8727):1345-7.
  56. Mahé A, Chollet-Martin S, Gessain A. HTLV-I-associated infective dermatitis. Lancet. 1999;354:1386.
  57. Hlela C, Graham N, Bhigjee AI, Taylor GP, Khumalo NP, Mosam A. Human T cell lymphotropic virus type 1- associated infective dermatitis in KwaZulu Natal, South Africa. BMC Dermatol. 2013;13:11.
  58. Einsiedel L, Cassar O, Gordon L, Gessain A. Human T-lymphotropic virus type 1 infective dermatitis in central Australia. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2013;57(4):370-3.
  59. Menz F, Menz J, Wilson K, Turpin J, Bangham C, Einsiedel L. Infective dermatitis associated with human T-lymphotropic virus type 1 infection in Adelaide, South Australia. The Australasian journal of dermatology. 2017.
  60. Murphy EL, Wilks R, Morgan OS, Hanchard B, Cranston B, Figueroa JP, et al. Health effects of human T-lymphotropic virus type I (HTLV-I) in a Jamaican cohort. Int J Epidemiol. 1996;25(5):1090-7.
  61. Araujo AQ, Andrade-Filho AS, Castro-Costa CM, Menna-Barreto M, Almeida SM. HTLV-I-associated myelopathy/tropical spastic paraparesis in Brazil: a nationwide survey. HAM/TSP Brazilian Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19(5):536-41.
  62. Maloney EM, Cleghorn FR, Morgan OS, Rodgers-Johnson P, Cranston B, Jack N, et al. Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(2):167-70.
  63. Taylor GP, Tosswill JH, Matutes E, Daenke S, Hall S, Bain BJ, et al. Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr. 1999;22(1):92-100.
  64. Orland JR, Engstrom J, Fridey J, Sacher RA, Smith JW, Nass C, et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology. 2003;61(11):1588-94.
  65. Tanajura D, Castro N, Oliveira P, Neto A, Muniz A, Carvalho NB, et al. Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study. Clin Infect Dis. 2015;61(1):49-56.
  66. Martin F, Fedina A, Youshya S, Taylor GP. A 15-year prospective longitudinal study of disease progression in patients with HTLV-1 associated myelopathy in the UK. J Neurol Neurosurg Psychiatry. 2010;81(12):1336-40.
  67. Zihlmann KF, de Alvarenga AT, Casseb J. Living invisible: HTLV-1-infected persons and the lack of care in public health. PLoS neglected tropical diseases. 2012;6(6):e1705.
  68. Steinfort DP, Brady S, Weisinger HS, Einsiedel L. Bronchiectasis in Central Australia: a young face to an old disease. Respir Med. 2008;102(4):574-8.
  69. Einsiedel L, Fernandes L. Strongyloides stercoralis: a cause of morbidity and mortality for indigenous people in Central Australia. Internal medicine journal. 2008;38(9):697-703.
  70. Einsiedel LJ, Pepperill C, Wilson K. Crusted scabies: a clinical marker of human T-lymphotropic virus type 1 infection in central Australia. The Medical journal of Australia. 2014;200(11):633-4.
  71. Chew R, Henderson T, Aujla J, Whist E, Einsiedel L. Turning a blind eye: HTLV-1-associated uveitis in Indigenous adults from Central Australia. International ophthalmology. 2017.
  72. Einsiedel L, Pham H, Wilson K, Walley R, Turpin J, Bangham C, et al. Human T-Lymphotropic Virus type 1c subtype proviral loads, chronic lung disease and survival in a prospective cohort of Indigenous Australians. PLoS neglected tropical diseases. 2018;12(3):e0006281.
  73. Prasetyo AA, Dirgahayu P, Sari Y, Hudiyono H, Kageyama S. Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia. J Infect Dev Ctries. 2013;7(6):453-67.
  74. Wiktor SZ, Cannon RO, Atkinson WL, Lutz B, Hook EW, 3rd, Blattner WA, et al. Infection with human T lymphotropic virus types I and II in sexually transmitted disease clinics in Baltimore and New Orleans. J Infect Dis. 1992;165(5):920-4.
  75. Turner CG, Cohen CE, Sabin CA, Tosswill JH, Best JM, Taylor GP, et al. The seroepidemiology of HTLV-I amongst genitourinary medicine (GUM) attendees in South East London. J Clin Virol. 2008;43(2):253-4.
  76. Fukushima Y, Takahashi H, Naksono T, Extraordinary high seropositivity rates of human T-cell lymphotropic virus type II (HTLV-II) in intravenous drug users in South Vietnam. AIDS Res Hum Retrovirol. 1995;11:637-44.
  77. Khabbaz R, Darrow W, Hartley T, Witte J, Cohen J, French J, et al. Seroprevalence and risk factors for HTLV-I/II infection among female prostitutes in the United States. JAMA. 1990;263(1):60-4.
  78. Khabbaz RF, Douglas JM, Jr., Judson FN, Spiegel RA, St Louis ME, Whittington W, et al. Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA. J Infect Dis. 1990;162(1):241-4.
  79. Briggs NC, Battjes RJ, Cantor KP, Blattner WA, Yellin FM, Wilson S, et al. Seroprevalence of human T cell lymphotropic virus type II infection, with or without human immunodeficiency virus type 1 coinfection, among US intravenous drug users. J Infect Dis. 1995;172(1):51-8.
  80. Bessinger R, Beilke M, Kissinger P, Jarrott C, Tabak O. Retroviral coinfections at a New Orleans HIV outpatient clinic. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:67-71.
  81. Magnani G, Elia G, Casoli C, Calzetti C, Degli Antoni A, Fiaccadori F. HTLV-II does not adversely affect the natural history of HIV-1 infection in intravenous drug users. Infection. 1995;23(1):63.
  82. Hershow RC, Galai N, Fukuda K, Graber J, Vlahov D, Rezza G, et al. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis. 1996;174(2):309-17.
  83. Beilke MA, Theall KP, O'Brien M, Clayton JL, Benjamin SM, Winsor EL, et al. Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004;39(2):256-63.
  84. Brites C, Harrington W, Jr., Pedroso C, Martins NE, Badaro R. Epidemiological Characteristics of HTLV-I and II Co-Infection in Brazilian Subjects Infected by HIV-1. Braz J Infect Dis. 1997;1(1):42-7.
  85. Brites C, Pedroso C, Netto E, Harrington W, Jr., Galvao-Castro B, Couto-Fernandez JC, et al. Co-Infection by HTLV-I/II is Associated With Increased Viral Load in PBMC of HIV-1 Infected Patients in Bahia, Brazil. Braz J Infect Dis. 1998;2(2):70-7.
  86. Brites C, Sampalo J, Oliveira A. HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression. AIDS Rev. 2009;11(1):8-16.
  87. Brites C, Alencar R, Gusmao R, Pedroso C, Netto EM, Pedral-Sampaio D, et al. Co-infection with HTLV-1 is associated with a shorter survival time for HIV-1-infected patients in Bahia, Brazil. AIDS. 2001;15(15):2053-5.
  88. Pedroso C, Netto EM, Weyll N, Brites C. Coinfection by HIV-1 and human lymphotropic virus type 1 in Brazilian children is strongly associated with a shorter survival time. J Acquir Immune Defic Syndr. 2011;57 Suppl 3:S208-11.
  89. Beilke MA, Japa S, Moeller-Hadi C, Martin-Schild S. Tropical spastic paraparesis/human T leukemia virus type 1-associated myelopathy in HIV type 1-coinfected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2005;41(6):e57-e63.
  90. Casseb J, Posada-Vergara MP, Montanheiro P, Fukumori LM, Olah I, Smid J, et al. T CD4+ cells count among patients co-infected with human immunodeficiency virus type 1 (HIV-1) and human T-cell leukemia virus type 1 (HTLV-1): high prevalence of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). Rev Inst Med Trop Sao Paulo. 2007;49(4):231-3.
  91. Martin F, Tagaya Y, Gallo R. Time to eradicate HTLV-1: an open letter to WHO. Lancet. 2018;391(10133):1893-4.
  92. Martin F, Gallo R. Time to eradicate HTLV-1: an open letter to WHO: Global Virus Network; 2018 [Available from:
  93. Chiyoda S, Kinoshita K, Egawa S, Inoue J, Watanabe K, Ifuku M. Decline in the positive rate of human T-lymphotropic virus type-1 (HTLV-1) antibodies among blood donors in Nagasaki. Intern Med. 2001;40(1):14-7.
  94. Hino S. Establishment of the milk-borne transmission as a key factor for the peculiar endemicity of human T-lymphotropic virus type 1 (HTLV-1): the ATL Prevention Program Nagasaki. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(4):152-66.
  95. Olindo S, Jeannin S, Saint-Vil M, Signate A, Edimonana-Kaptue M, Joux J, et al. Temporal trends in Human T-Lymphotropic virus 1 (HTLV-1) associated myelopathy/tropical spastic paraparesis (HAM/TSP) incidence in Martinique over 25 years (1986-2010). PLoS neglected tropical diseases. 2018;12(3):e0006304.
  96. Iwanaga M, Chiyoda S, Kusaba E, Kamihira S. Trends in the seroprevalence of HTLV-1 in Japanese blood donors in Nagasaki Prefecture, 2000-2006. Int J Hematol. 2009;90(2):186-90.
  97. Styles CE, Hoad VC, Seed CR. Estimation of human T-lymphotropic virus incidence in blood donors from observed prevalence. Vox Sang. 2018;113(8):814-5.
  98. Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019;37(8):677-87.